In statehouses around the country, some of the nation's biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.
Biotech firms lobby states to limit generics
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.